Case Report on Acute Lymphoblastic Leukemia B-Cell (original) (raw)
Related papers
Acute lymphoblastic leukaemia (ALL
Acute lymphoblastic leukaemia (ALL) is a type of blood cancer that starts from white blood cells called lymphocytes in the bone marrow. Adults and children can get it but it is most often diagnosed in younger people. Chemotherapy is the main treatment. Some people need to have a stem cell transplant. Childhood acute lymphoblastic leukaemia (ALL) What is childhood acute lymphoblastic leukaemia (ALL) ?
B-acute lymphoblastic leukaemia
BMJ case reports, 2014
A 13-year-old boy presented with fever, skeletal pain, polydipsia, polyuria and multiple osteolytic lesions in pelvic bones and upper femur. There was no organomegaly or lymphadenopathy. His serum calcium levels were raised. Peripheral blood film examination was normal. Bone marrow showed presence of blast cells. Flowcytometry indicated B-acute lymphoblastic leukaemia (B-ALL). Hypercalcaemia and osteolytic lesions are rare presentations of B-ALL. This should be kept as a differential if a child presents with unexplained skeletal pain with lytic lesions.
European Journal of Cancer Care, 2005
Our goal was to identify and summarize the published literature pertaining to the incidence, prevalence, mortality, aetiology, clinical diagnosis, and management of acute lymphoblastic leukaemia (ALL). Acute lymphoblastic leukaemia represents 12% of all leukaemia cases, with a worldwide incidence projected to be 1-4.75 per 100 000 people. Italy, the United States (US), Switzerland, and Costa Rica are the countries with the highest incidence of ALL. Hereditary link, genetic defects, and possibly radiation or chemical exposures are listed amongst the most significant risk factors. Acute lymphoblastic leukaemia is predominantly a disease of childhood, but it affects adults as well. It accounts for 80% of all leukaemia cases in children. The incidence is slightly higher in men than in women and greater in white people than in black people. In 2003 in the US, there were an estimated 5800 deaths from ALL. Presenting signs and symptoms of ALL are fairly non-specific and include fever, anaemia, petechiae, and bone and joint pain. Staging of the disease and patient risk profile are routinely performed to define ALL subtypes and guide management. Chemotherapy, cranial radiation in patients with high-risk disease, and stem cell transplantation for selected patients are the prevalent therapies. Complete remission rates are high, especially amongst children (even 100%); however, long-term survival at 10 years (event-free survival) is in the range of 63% for children and 25-35% for adults. This implies that there is still a strong need for new therapies to maintain remission and prolong survival. Future treatment strategies may be driven by the patient's minimal residual disease status, a measure that more precisely defines remission, prognosis, responsiveness to therapy, and expected long-term survival.
Acute Lymphocytic Leukemia in Adults. Pathologic Features and Prognosis
Romanian journal of internal medicine = Revue roumaine de médecine interne
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm of the lymphocyte precursor cells. Among adults it is a relatively rare neoplasm with a curability rate around 30% at 5 years. Currently, the diagnosis and classification of ALL is a multistep procedure that relies on the simultaneous application of multiple techniques that include: cytomorphology, immunophenotype and cytogenetic assays. Some of them have important clinical implications for both diagnosis and predicting response to specific treatment regimens, while the role of others is still to be defined. Over the years, several prognostic factors have been identified and today a risk stratification at diagnosis and during the follow-up is based on the characteristics of the leukemic cells.
Clinicopathological Study of Acute Lymphoblastic Leukemia - a Multiparameter Study
Journal of Evidence Based Medicine and Healthcare, 2015
BACKGROUND Acute Lymphoblastic Leukaemia (ALL), a malignancy of lymphoid lineage cells, has excellent prognosis in children. Leukemia is the most prevalent childhood cancer and Acute Lymphoblastic Leukemia (ALL) constitutes 75% of all cases. The most frequent presenting symptoms are fever, weight loss and pallor. Early detection of clinical symptoms positively affects timely diagnosis. AIMS & OBJECTIVES The objectives of the present study were to assess frequency of presenting symptoms, laboratory data and prognostic factors in children with diagnosis of ALL. MATERIALS & METHODS The present study (2014) was performed in the hematology section of Department of Pathology of Gajra Raja Medical College, Gwalior over a period of 12 months from 1st October 2013 to 30th September 2014. This was a prospective study. The blood samples were received from various departments of Jayarogya hospital especially from the Pediatric and Medicine departments. RESULTS Out of the 37 cases diagnosed as Acute Lymphoblastic Leukemia, 25(67.57%) were male and 12(32.43%), were female, (male:female ratio: 2.1:1). 43.35% of patients which comprises highest number of cases belonged to 11-20 years of age group. The most frequent presenting symptoms was fever (83.78%) followed by weakness (70.27%) and loss of appetite (27% while most frequent presenting sign was pallor (86.48%) followed by lymphadenopathy (67.57%) and splenomegaly (48.65%)). Complete blood cell count was abnormal in all of the patients, and pancytopenia was detected in 10.81% of the patients. Of all the patients, 91.89% had abnormal white blood cell (WBC) count at presentation, 10.81% had leucopenia and 80% had leucocytosis. FAB L1 subtype was more common as compared to FAB L2 subtype. CONCLUSION In our study (2014), Acute Lymphoblastic Leukemia was more prevalent in males than in females and more common in childhood than in adult. FAB L1 subtype was more common as compared to FAB L2 subtype.
Prognostic Factors Of Adults B-Cell Acute Lymphoblastic Leukemia
Sohag Medical Journal, 2017
Background. B-cell acute lymphoblastic leukemia (B-ALL) is a malignancy of immature B-cell precursors that proliferate in the bone marrow leading to signs and symptoms of bone marrow failure. Clinical, biological and genetic features are having prognostic significance affecting the outcome of those patients. We aimed with this study to analyze the significance of these factors in affecting patients outcome after treatment with complete or incomplete remission. Patients and methods. This study was carried out on 39 adults B-cell ALL patients who were attending the hematology oncology clinics. All patients were subjected to; History, clinical examination and Laboratory investigations, which included CBC, PB and BM examination, Immunophenotyping and Fluorescence in situ hybridization. Results. This study was carried out on 39 adult B-cell ALL patients (Follow up was done at day 28 of chemotherapy) show: 16 (41%) patients achieved complete remission (CR) ; while 23 (59%) patients showed incomplete remission (IR). Statistical analysis of patients' outcome with prognostic markers revealed significant association (p<0.05) of CR with TLC <50x109/L (p=0.003) , age <35 yrs (p=0.000) and frequency of t(9;22) with (p=0.05). Conclusion. Age, TLC and t(9;22) are represent the most significant standard prognostic factors in relation to adults BALL patients' outcome.
Improved outcome in adult B-cell acute lymphoblastic leukemia
Blood
A total of 68 adult patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated in three consecutive adult multicenter ALL studies. The diagnosis of B-ALL was confirmed by L3 morphology and/or by surface immunoglobulin (Slg) expression with > 25% blast cell infiltration in the bone marrow (BM). They were characterized by male predominance (78%) and a median age of 34 years (15 to 65 y) with only 9% adolescents (15 to 20 y), but 28% elderly patients (50 to 65 y). The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood B-ALL with six short, intensive 5-day cycles, alternately A and B. In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of cyclophosphamide 200 mg/m2 for 5 days, intermediate-dose methotrexate (IdM) 500 mg/m2 (24 hours), in addition to cytarabine (AraC), teniposide (VM26) and prednisone. Cycle B was similar except that AraC and VM26 were replaced by doxorubicin. Major chan...
The Professional Medical Journal
Objectives: The aim of the present study is to evaluate the frequencyof chromosomal abnormalities in childhood acute lymphoblastic leukemia at a tertiarycare hospital of Sindh. Study design: Observation study. Place of study: Isra UniversityHospital, Hyderabad and Oncology Unit Liaquat University of Medical and Health Sciences,Jamshoro. Duration of study: From January 2014 to March 2015. Materials and Methods:Cytogenetic analysis was conducted on peripheral blood and bone marrow samples of 100diagnosed cases of acute lymphoblastic leukemia (ALL). Peripheral blood and bone marrowsamples were collected and putted into sodium heparinized bottles. Cytogenetic analysiswas performed by karyotyping according to the ISCN guidelines for human cytogeneticnomenclature using cytovision-+ system for image analysis. Data was analyzed on statistic8.1 USA and expressed as means, percentage and chi-square with P-value of ≤ 0.05 beingdefined significant. Results: Chromosomal abnormalities were found ...
[Analysis of clinical-biological features of adult acute lymphoblastic leukemia]
Gaceta medica de Mexico, 2015
INTRODUCCTION Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by a proliferation of immature cells. In immunophenotypic, cytogenetic and molecular studies, it is a heterogeneous disease with diverse manifestations and prognoses. The treatment is complex and is associated with complications during its course. PATIENTS AND METHODS A prospective study of cohort of patients with ALL. Subjects were recruited consecutively from April 2010 to November 2012 in the Specialties Hospital, /MSS. RESULTS We included 29 patients with ALL; of 16 females (55%) and 13 males (45%), 18 (64%) were treated with modified BFM, seven (25%) HiperCVAD, and three (11 %) others. In all, 70% achieved complete remission, and 8.5% partial responses. Induction mortality in five patients (17%). Consolidation mortality in three (13%). Relapse 33%, with a mean of eight months (5- 16 months), overall survival five months. At 26 months of follow-up, 13 patients (45%) maintained RC. Disease-free sur...